CH603615A5 - - Google Patents

Info

Publication number
CH603615A5
CH603615A5 CH452674A CH452674A CH603615A5 CH 603615 A5 CH603615 A5 CH 603615A5 CH 452674 A CH452674 A CH 452674A CH 452674 A CH452674 A CH 452674A CH 603615 A5 CH603615 A5 CH 603615A5
Authority
CH
Switzerland
Application number
CH452674A
Inventor
Roger Alan Parker
Original Assignee
Richardson Merrell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Merrell Inc filed Critical Richardson Merrell Inc
Publication of CH603615A5 publication Critical patent/CH603615A5/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
CH452674A 1973-04-02 1974-04-01 CH603615A5 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/347,232 US4000164A (en) 1973-04-02 1973-04-02 Hypolipidemic agents

Publications (1)

Publication Number Publication Date
CH603615A5 true CH603615A5 (xx) 1978-08-31

Family

ID=23362868

Family Applications (1)

Application Number Title Priority Date Filing Date
CH452674A CH603615A5 (xx) 1973-04-02 1974-04-01

Country Status (13)

Country Link
US (1) US4000164A (xx)
JP (1) JPS5844663B2 (xx)
AU (1) AU473144B2 (xx)
BE (1) BE813041A (xx)
CA (1) CA1031355A (xx)
CH (1) CH603615A5 (xx)
DE (1) DE2414252A1 (xx)
FR (1) FR2223031B1 (xx)
GB (1) GB1417103A (xx)
NL (1) NL7404218A (xx)
PH (1) PH24978A (xx)
SE (1) SE415255B (xx)
ZA (1) ZA741421B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032647A (en) * 1975-06-16 1977-06-28 Richardson-Merrell Inc. Substituted thenoylacetic acid and esters
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
GB1540917A (en) * 1976-08-06 1979-02-21 Wassermann Spa A Furan derivatives for use as pharmaceutical products particularly for the treatment of rheumatic illnesses and a method for their preparation
CA1104574A (en) * 1976-12-20 1981-07-07 Roger A. Parker Antirhinovirus agents
US4169202A (en) * 1978-06-05 1979-09-25 American Home Products Corporation Process for preparing 4,5-dihydro-4-oxofuran-2-carboxylic acid derivatives
US4980371A (en) * 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
US4977185A (en) * 1988-12-21 1990-12-11 Merrell Dow Pharmaceuticals Antiretroviral aryloxy substituted furan ketones
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834789A (en) * 1955-02-15 1958-05-13 Sadolin & Holmblad As Process of preparing lower lakyl 2, 3, 6-trihydroxybenzoate, and intermediates therefor

Also Published As

Publication number Publication date
DE2414252C2 (xx) 1988-02-18
BE813041A (fr) 1974-07-15
AU473144B2 (en) 1976-06-17
FR2223031A1 (xx) 1974-10-25
ZA741421B (en) 1975-01-29
AU6649674A (en) 1975-09-11
FR2223031B1 (xx) 1977-01-21
CA1031355A (en) 1978-05-16
JPS5844663B2 (ja) 1983-10-04
US4000164A (en) 1976-12-28
JPS49127964A (xx) 1974-12-07
DE2414252A1 (de) 1974-10-17
NL7404218A (xx) 1974-10-04
PH24978A (en) 1990-12-26
SE415255B (sv) 1980-09-22
GB1417103A (en) 1975-12-10

Similar Documents

Publication Publication Date Title
AR201758A1 (xx)
AU465372B2 (xx)
AR201235Q (xx)
AR201231Q (xx)
AU474593B2 (xx)
AU474511B2 (xx)
AU474838B2 (xx)
AU465453B2 (xx)
AU471343B2 (xx)
AU450229B2 (xx)
FR2223031B1 (xx)
AU476714B2 (xx)
AR201229Q (xx)
AU472848B2 (xx)
AU466283B2 (xx)
AU476696B2 (xx)
AU477823B2 (xx)
AU477824B2 (xx)
AR210729A1 (xx)
AU476873B1 (xx)
AU461342B2 (xx)
AR200256A1 (xx)
AR193950A1 (xx)
AR201432A1 (xx)
AR200885A1 (xx)

Legal Events

Date Code Title Description
PL Patent ceased